{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T12:13:05Z","timestamp":1747224785999,"version":"3.40.5"},"reference-count":84,"publisher":"Informa UK Limited","issue":"2","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Pharm. Pat. Anal."],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.4155\/ppa-2020-0022","type":"journal-article","created":{"date-parts":[[2021,4,8]],"date-time":"2021-04-08T16:04:04Z","timestamp":1617897844000},"page":"83-98","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":3,"title":["Vaccines Against Antimicrobial Resistance: a Promising Escape Route for Multidrug Resistance"],"prefix":"10.1080","volume":"10","author":[{"given":"Absar","family":"Talat","sequence":"first","affiliation":[{"name":"Medical Microbiology & Molecular Biology Lab., Interdisciplinary Biotechnology Unit, AMU, Aligarh, 202002, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9191-9423","authenticated-orcid":false,"given":"Asad U","family":"Khan","sequence":"additional","affiliation":[{"name":"Medical Microbiology & Molecular Biology Lab., Interdisciplinary Biotechnology Unit, AMU, Aligarh, 202002, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2021,4,8]]},"reference":[{"key":"e_1_3_2_3_1","unstructured":"CDC's antibiotic resistance threats in the United States 2019 (2019 AR threats report). https:\/\/www.cdc.gov\/drugresistance\/biggest-threats.html"},{"key":"e_1_3_2_4_1","unstructured":"World Health Organization . Media Centre. WHO publishes list of bacteria for which new antibiotics are urgently needed. (2017). http:\/\/www.who.int\/mediacentre\/news\/releases\/2017\/bacteria-antibiotics-needed\/en\/"},{"issue":"4","key":"e_1_3_2_5_1","first-page":"401","article-title":"Introduction","volume":"87","author":"Czochor J","year":"2014","unstructured":"Czochor J , TurchickA. Introduction. Yale J. Biol. Med.87(4), 401\u2013402 (2014).","journal-title":"Yale J. Biol. Med."},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/131.5.553"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1054\/tuld.1999.0206"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1128\/iai.55.5.1116-1120.1987"},{"key":"e_1_3_2_9_1","unstructured":"Sinclair A XieX DendukuriN. The use of Lactobacillus probiotics in the prevention of antibiotic associated Clostridium difficile diarrhea: an update. McGill University Health Centre Technology Assessment Unit (2011). https:\/\/muhc.ca\/sites\/default\/files\/micro\/m-TAU\/muhc_tau_2011_54_probiotic.pdf"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.66.12.5698-5702.1998"},{"key":"e_1_3_2_11_1","article-title":"Manual for the surveillance of vaccine-preventable diseases","author":"Tiwari T","year":"2011","unstructured":"Tiwari T . Manual for the surveillance of vaccine-preventable diseases. Chapter 16: Tetanus (2011). https:\/\/www.cdc.gov\/vaccines\/pubs\/surv-manual\/chpt16-tetanus.html","journal-title":"Chapter 16: Tetanus"},{"key":"e_1_3_2_12_1","first-page":"69","article-title":"Use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines: updated recommendations of the Advisory Committee on Immunization Practices \u2013 United States, MMWR","volume":"2020","author":"Havers FP","year":"2019","unstructured":"Havers FP . Use of tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccines: updated recommendations of the Advisory Committee on Immunization Practices \u2013 United States, MMWR. Morbidity and Mortality Weekly Report2020, 69 (2019).","journal-title":"Morbidity and Mortality Weekly Report"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00458-13"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-199605000-00009"},{"key":"e_1_3_2_15_1","volume-title":"StatPearls 14.","author":"Brundage HL","year":"2020","unstructured":"Brundage HL , MukkaSK. Haemophilus influenza Type B vaccine. In: StatPearls 14.StatPearls Publishing, FL, USA (2020)."},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/adc.86.6.396"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268812000957"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8010132"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000002832"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy1103"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix1145"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1900236"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2018.11.073"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/jam.12423"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00474-2"},{"key":"e_1_3_2_26_1","unstructured":"World Bank Group . World Bank Group drug-resistant infections: a threat to our economic future. World Bank WA USA (2017)."},{"key":"e_1_3_2_27_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1717162115"},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00428-16"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12887-018-1332-3"},{"issue":"1","key":"e_1_3_2_30_1","first-page":"e1","article-title":"Estimating the proportion of bystander selection for antibiotic resistance among potentially pathogenic bacterial flora","volume":"124","author":"Tedijantoa C","year":"2018","unstructured":"Tedijantoa C , OlesenbSW , GradbYH , LipsitchaM. Estimating the proportion of bystander selection for antibiotic resistance among potentially pathogenic bacterial flora. Young Children124(1), e1 (2018).","journal-title":"Young Children"},{"key":"e_1_3_2_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)71081-3"},{"key":"e_1_3_2_32_1","unstructured":"CDC . Centers for disease control and prevention national center for emerging and zoonotic infectious diseases (NCEZID) Division of Foodborne Waterborne and Environmental Diseases (DFWED)."},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(92)90030-N"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1097\/INF.0000000000001145"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1128\/jb.144.1.444-446.1980"},{"key":"e_1_3_2_36_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/158.2.372"},{"key":"e_1_3_2_37_1","unstructured":"The Centers for Disease Control and Prevention. https:\/\/www.cdc.gov\/cholera\/vaccines.html"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF01963109"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2305.162034"},{"key":"e_1_3_2_40_1","article-title":"Klebsiella pneumonia","author":"Ashurst JV","year":"2020","unstructured":"Ashurst JV , DawsonA. Klebsiella pneumonia. StatPearls. (2020). https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK519004\/","journal-title":"StatPearls."},{"issue":"7","key":"e_1_3_2_41_1","first-page":"934","article-title":"Treatment options for colistin resistant Klebsiella pneumoniae: present and future","volume":"8","author":"Petrosillo N","year":"2019","unstructured":"Petrosillo N , TagliettiF , GranataG. Treatment options for colistin resistant Klebsiella pneumoniae: present and future. Clin. Med.8(7), 934 (2019).","journal-title":"Clin. Med."},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1907833116"},{"key":"e_1_3_2_43_1","unstructured":"Research programme: Klebsiella pneumoniae vaccine \u2013 Syntiron . Latest information update: 23 Jan 2018. https:\/\/adisinsight.springer.com\/drugs\/800051160"},{"key":"e_1_3_2_44_1","unstructured":"Boston Consulting Group . https:\/\/vaccinesforamr.org\/"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(17)30108-1"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00555-20"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.15.2.194-222.2002"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0702403104"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/174.3.537"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.4161\/hv.26565"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0b013e31825334f6"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkr046"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-17099-2"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.09.30"},{"key":"e_1_3_2_55_1","unstructured":"Novadigm Therapeutics Inc. [US\/US] : WO 2013\/015831 Al (2013)."},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00700-08"},{"key":"e_1_3_2_57_1","unstructured":"Business wire group . https:\/\/www.businesswire.com\/news\/home\/20180419005611\/en\/NovaDigm-Therapeutics-Announces-Initiation-Phase-2a-Clinical"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00399-16"},{"key":"e_1_3_2_59_1","unstructured":"Pharma Letter Group . https:\/\/www.thepharmaletter.com\/"},{"key":"e_1_3_2_60_1","doi-asserted-by":"publisher","DOI":"10.20411\/pai.v3i1.231"},{"key":"e_1_3_2_61_1","unstructured":"Mico Bio Inc. : US8394389 B2 (2013)."},{"key":"e_1_3_2_62_1","unstructured":"Statens Serum Institut : US9526773 B2 (2016)."},{"key":"e_1_3_2_63_1","unstructured":"Aeras Global TB Vaccine Foundation : US7670609 B2 (2010)."},{"key":"e_1_3_2_64_1","unstructured":"Statens Serum Institut : USRE46583 E (2017)."},{"key":"e_1_3_2_65_1","unstructured":"Statens Serum Institut : US8293250 B2 (2012)."},{"key":"e_1_3_2_66_1","unstructured":"Statens Serum Institut : US9074001 B2."},{"key":"e_1_3_2_67_1","unstructured":"Havenga MJE RijnAad VogelsRet al. US8202.723 B2 (2012)."},{"key":"e_1_3_2_68_1","unstructured":"Council of Scientific and Industrial Research : US6783765 B2 (2004)."},{"key":"e_1_3_2_69_1","unstructured":"Albert Einstein College of Medicine of Yeshiva University President and Fellows of Harvard College : US7758874 B2 (2010)."},{"key":"e_1_3_2_70_1","unstructured":"Statens Serum Institut : US8142797 B2 (2012)."},{"key":"e_1_3_2_71_1","unstructured":"Crucell Holland B.V Aeras Global TB Vaccine Foundation : US 8012.467 B2 (2011)."},{"key":"e_1_3_2_72_1","unstructured":"The Regents of the University of California : US6471967 B1 (2002)."},{"key":"e_1_3_2_73_1","unstructured":"Universidad de Zaragoza : US 8287886 B2 (2012)."},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40272-016-0208-y"},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00018-12"},{"key":"e_1_3_2_76_1","first-page":"1148","article-title":"Centers for Disease Control and Prevention (CDC) progress in introduction of pneumococcal conjugate vaccine-Worldwide, 2000\u20132008","volume":"57","author":"CDC","year":"2008","unstructured":"CDC . Centers for Disease Control and Prevention (CDC) progress in introduction of pneumococcal conjugate vaccine-Worldwide, 2000\u20132008. Morb. Mortal. Wkly Rep.57, 1148\u20131151 (2008).","journal-title":"Morb. Mortal. Wkly Rep."},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jir755"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40266-013-0060-5"},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa051642"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(14)71081-3"},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.1097\/00006454-200301000-00006"},{"key":"e_1_3_2_82_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1401914"},{"key":"e_1_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(13)70338-4"},{"key":"e_1_3_2_84_1","unstructured":"Merck . Merck announces first Phase III studies for PCV-15 (V114) its investigational pneumococcal disease vaccine (press release) (2018). https:\/\/www.merck.com\/news\/merck-announces-first-phase-three-studies-for-pcv-15-v114-its-investigational-pneumococcal-disease-vaccine\/"},{"key":"e_1_3_2_85_1","unstructured":"Pfizer announces top-line results from Phase III study of 20-valent pneumococcal conjugate vaccine in pneumococcal vaccine-na\u00efve adults aged 18 years or older (press release). Pfizer Inc (2020). https:\/\/markets.businessinsider.com\/news\/stocks\/pfizer-announces-top-line-results-from-phase-3-studPfizer%20announces%20top-line%20results%20from%20Phase%20III%20study%20of%2020-valent%20pneumococcal%20conjugate%20vaccine%20in%20pneumococcal%20vaccine-na%C3%AFve%20adults%20aged%2018%20years%20or%20older%20(press%20release).%20Pfizer%20Inc%20(2020)y-of-20-valent-pneumococcal-conjugate-vaccine-in-pneumococcal-vaccine-na-ve-adults-aged-18-years-or-older-1029010347"},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2011.09.128"}],"container-title":["Pharmaceutical Patent Analyst"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.4155\/ppa-2020-0022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,17]],"date-time":"2024-05-17T20:12:55Z","timestamp":1715976775000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.4155\/ppa-2020-0022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":84,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["10.4155\/ppa-2020-0022"],"URL":"https:\/\/doi.org\/10.4155\/ppa-2020-0022","relation":{},"ISSN":["2046-8954","2046-8962"],"issn-type":[{"type":"print","value":"2046-8954"},{"type":"electronic","value":"2046-8962"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ippa20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ippa20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-07-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}